Sen. Angus S. King Jr. Sells Thermo Fisher Scientific Inc. (NYSE:TMO) Stock

Senator Angus S. King Jr. (I-Maine) recently sold shares of Thermo Fisher Scientific Inc. (NYSE:TMO). In a filing disclosed on August 18th, the Senator disclosed that they had sold between $1,001 and $15,000 in Thermo Fisher Scientific stock on July 21st.

Senator Angus S. King Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 7/21/2025.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 7/21/2025.
• Purchased $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 7/21/2025.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 7/21/2025.
• Purchased $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 7/21/2025.
• Purchased $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 7/21/2025.
• Purchased $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 7/21/2025.
• Purchased $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 7/21/2025.
• Purchased $1,001 – $15,000 in shares of PayPal (NASDAQ:PYPL) on 7/21/2025.
• Purchased $1,001 – $15,000 in shares of Quanta Services (NYSE:PWR) on 7/21/2025.

Thermo Fisher Scientific Trading Down 2.0%

NYSE:TMO traded down $9.9380 during midday trading on Monday, hitting $490.0520. The stock had a trading volume of 462,365 shares, compared to its average volume of 2,471,620. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a market capitalization of $185.05 billion, a price-to-earnings ratio of 28.35, a PEG ratio of 2.67 and a beta of 0.74. The stock has a 50-day moving average of $443.02 and a 200 day moving average of $455.80. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter in the prior year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is 9.95%.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at approximately $52,037,916.68. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 18,896 shares of company stock valued at $8,593,838. Insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

Several large investors have recently added to or reduced their stakes in TMO. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $25,000. CBIZ Investment Advisory Services LLC lifted its holdings in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after purchasing an additional 33 shares during the period. Ameriflex Group Inc. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $30,000. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $30,000. Finally, Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $31,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

TMO has been the subject of a number of analyst reports. Raymond James Financial restated an “outperform” rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Barclays increased their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an “equal weight” rating in a research report on Thursday, July 24th. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research report on Thursday, July 24th. Argus dropped their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. Finally, HSBC reaffirmed a “hold” rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $593.00.

About Senator King

Angus King (independent) is a member of the U.S. Senate from Maine. He assumed office on January 3, 2013. His current term ends on January 3, 2031.

King (independent) ran for re-election to the U.S. Senate to represent Maine. He won in the general election on November 5, 2024.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.